Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, announced that Christopher Hepler, Manager, Catalent Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held at the Mayflower Hotel, Washington, D.C. on Jan 28 – 30, 2020.
On Tuesday, Jan. 28 at 12:50 p.m., Mr. Hepler will present “Conversion of a Potency Assay from Cell-Based Binding to AlphaLISA®”*, and using a case study, explain how the AlphaLISA® platform can develop a relative potency assay that, is more accurate, quicker and easier to execute than the original FACS-based assay.
Mr. Hepler received his bachelor’s degree in animal science and master’s degree in physiology from North Carolina State University, and has been working in the pharmaceutical and biopharmaceutical industry for more than 25 years. He is experienced in automation, as well as cell and molecular biology assay development, optimization, and validation. Mr. Hepler joined Catalent in 2016, and in his current role, manages the Biologics department for the Morrisville, RTP site.
For further information on this event, visit www.catalent.com/events/casss-wcbp
To arrange a meeting with Mr. Hepler or any of the other Catalent experts attending the event, contact Richard Kerns at NEPR – richard@nepr.agency
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.
